Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Anagrelide hydrochloride
Drug ID BADD_D00140
Description Anagrelide is a platelet-reducing agent used to lower dangerously elevated platelet levels (i.e. to treat thrombocythemia) in patients with myeloproliferative neoplasms.[L14153] It is an oral imidazoquinazoline that was first approved for use in the US in 1997.[A214274] It appears to carry a better response rate than other thrombocythemia treatments (e.g. [busulfan], [hydroxyurea]) and may be better tolerated.[A214274]
Indications and Usage Anagrelide is indicated for the treatment of thrombocythemia, secondary to malignant neoplasms, to reduce platelet count and the associated risk of thrombosis. It is also beneficial in the amelioration of thrombocythemia symptoms including thrombo-hemorrhagic events.[L14153]
Marketing Status approved
ATC Code L01XX35
DrugBank ID DB00261
KEGG ID D02933
MeSH ID C021139
PubChem ID 135413494
TTD Drug ID D0D1HW
NDC Product Code 63818-0425; 0172-5240; 0172-5241; 63552-005; 65841-106; 54092-063; 53104-7537; 42571-413
UNII YTM763Y5C8
Synonyms anagrelide | Agrylin | BL 4162A | Agrelin | anagrelide hydrochloride | imidazo(2,1-b)quinazolin-2(3H)-one, 6,7-dichloro-1,5-dihydro-, monohydrochloride | 6,7-dichloro-1,5-dihydroimidazo(2,1-b)quinazolin-2(3H)-one hydrochloride
Chemical Information
Molecular Formula C10H8Cl3N3O
CAS Registry Number 58579-51-4
SMILES C1C2=C(C=CC(=C2Cl)Cl)N=C3N1CC(=O)N3.Cl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.001---
Abdominal pain07.01.05.002--
Alanine aminotransferase increased13.03.04.005--
Alopecia23.02.02.001--
Amblyopia06.02.01.001---
Amnesia19.20.01.001; 17.03.02.001--
Anaemia01.03.02.001--
Angina pectoris24.04.04.002; 02.02.02.002--
Aphthous ulcer07.05.06.002---
Arrhythmia02.03.02.001---
Arthralgia15.01.02.001--
Aspartate aminotransferase abnormal13.03.04.009---
Asthenia08.01.01.001---
Asthma22.03.01.002; 10.01.03.010---
Back pain15.03.04.005--
Blood pressure diastolic abnormal13.14.03.009---
Blood pressure systolic decreased13.14.03.007---
Bronchitis22.07.01.001; 11.01.09.001--
Cardiac failure02.05.01.001--
Cardiovascular disorder02.11.01.010; 24.03.02.009---
Chest pain02.02.02.011; 22.12.02.003; 08.01.08.002---
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Constipation07.02.02.001--
Cough22.02.03.001--
Dehydration14.05.05.001--
Depression19.15.01.001--
Diarrhoea07.02.01.001--
Diplopia17.17.01.005; 06.02.06.002---
Dizziness02.11.04.006; 24.06.02.007; 17.02.05.003--
The 1th Page    1 2 3 4    Next   Last    Total 4 Pages